It is not clear whether EGFR T790M mutation in NSCLC patients who have relapsed from first- or second-generation EGFR-TKIs treatment is acquired during disease progression or develops from the pre-existing EGFR T790M clones in treatment-naïve patients as a minor population. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.